Evidence map›Paper›PMID 31368813›Full record

ReviewClinical trials (London, England)2019

Regulating impact on bystanders in clinical trials: An unsettled frontier.

Nir Eyal, Jonathan Kimmelman, Lisa G Holtzman, Marc Lipsitch

Abstract readReview
In one paragraph

Review in Clinical trials (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Principal Investigator Responsibility for Flagging Research with Dual-Use or Pandemic Risk.Applied biosafety : journal of the American Biological Safety Association · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nir EyalCenter for Population-Level Bioethics, Rutgers University, New Brunswick, NJ, USA.ORCID 0000-0003-1056-6609
Jonathan KimmelmanBiomedical Ethics Unit, Department of Social Studies of Medicine, McGill University, Montreal, QC, Canada.ORCID 0000-0003-1614-6779
Lisa G HoltzmanDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Marc LipsitchDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Funding

HIV cure studies: risk, risk perception, and ethicsR01AI114617 · NIAID · RUTGERS BIOMEDICAL/HEALTH SCIENCES-RBHS · PI EYAL, NIR · 2015 to 2018
$3.2M
NIAID NIH HHS R01 AI114617Wellcome TrustWellcome Trust 208766/Z/17/Z
6 · The paper itself

Abstract

This article informally reviews key research ethics guidelines and regulations, academic scholarship, and research studies and finds wide variety in how they consider risk to bystanders in medical research (namely, non-participants whom studies nevertheless place at risk). Some of these key sources give no or very little consideration to bystanders, while others offer them the utmost protection (greater than they offer study participants). This unsettled frontier would benefit from a deeper investigation of the ethics of protecting research bystanders.

Indexed as

Clinical Trials as TopicEthics, ResearchGuidelines as TopicHumansInformed ConsentRiskTherapeutic Human Experimentationbystanderclinical ethicsclinical trialshuman research subject protectionResearch ethicsresearch nonparticipantthird party consent

Identifiers

PMID31368813
PMCPMC6742522

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.